|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2,162.00 JPY | +1.05% |
|
+0.79% | +3.30% |
| 06-30 | Trump's push for the world's lowest drug prices hits snag with mid-sized companies | RE |
| 06-26 | Lupin Receives U.S. FDA Tentative Approval for Enzalutamide Tablets | MT |
| Market Cap | 3,833B 23.82B 20.82B 19.11B 17.83B 33.79B 2,268B 34.36B 230B 89.19B 1,112B 89.45B 87.5B | P/E 2027 * |
11.1x | P/E 2028 * | 11.8x |
|---|---|---|---|---|---|
| Enterprise Value | 3,756B 23.34B 20.4B 18.73B 17.47B 33.12B 2,222B 33.67B 226B 87.41B 1,090B 87.66B 85.75B | EV / Sales 2027 * |
1.67x | EV / Sales 2028 * | 1.66x |
| Free-Float |
98.88% | Yield 2027 * |
3.76% | Yield 2028 * | 3.87% |
Last Transcript: Astellas Pharma Inc.
| 1 day | +1.05% | ||
| 1 week | +0.79% | ||
| Current month | -0.60% | ||
| 1 month | +0.09% | ||
| 3 months | -16.43% | ||
| 6 months | +1.50% | ||
| Current year | +3.30% |
| 1 week | 2,105 |  | 2,204 |
| 1 month | 2,041 | | 2,204 |
| Current year | 2,041 | | 2,717 |
| 1 year | 1,365 | | 2,717 |
| 3 years | 1,243.5 | | 2,717 |
| 5 years | 1,243.5 | | 2,717 |
| 10 years | 1,243.5 | | 2,717 |
| Manager | Title | Age | Since |
|---|---|---|---|
Naoki Okamura
CEO | Chief Executive Officer | 63 | 10/02/2023 |
Kitamura Atsushi
DFI | Director of Finance/CFO | 54 | 01/11/2023 |
Tatjana Dragovic
CMP | Compliance Officer | - | 01/04/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
Kenji Yasukawa
CHM | Chairman | 66 | 10/02/2023 |
Naoki Okamura
BRD | Director/Board Member | 63 | 01/06/2019 |
| Director/Board Member | 58 | 01/06/2023 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.05% | +0.79% | +55.37% | +0.82% | 23.82B | |
| +1.86% | +7.65% | +55.77% | +158.84% | 1,082B | |
| +3.57% | +7.42% | +69.09% | +58.92% | 633B | |
| +3.99% | +7.37% | +36.87% | +93.77% | 461B | |
| -1.20% | -1.94% | +26.41% | +20.22% | 339B | |
| +4.94% | +3.39% | +39.92% | +28.93% | 301B | |
| +2.42% | +1.60% | +30.06% | +42.24% | 292B | |
| +2.47% | +5.18% | -24.80% | -39.60% | 225B | |
| +3.55% | +6.05% | +26.04% | +68.52% | 202B | |
| +4.21% | +6.00% | +17.72% | +70.33% | 163B | |
| Average | +2.21% | +4.03% | +33.25% | +50.30% | 372.35B | |
| Weighted average by Cap. | +1.85% | +5.18% | +41.57% | +79.72% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 2,250B 13.99B 12.22B 11.22B 10.46B 19.84B 1,331B 20.17B 135B 52.36B 653B 52.51B 51.37B | 2,072B 12.88B 11.25B 10.33B 9.63B 18.27B 1,226B 18.57B 124B 48.21B 601B 48.35B 47.3B |
| Net income | 345B 2.14B 1.87B 1.72B 1.6B 3.04B 204B 3.09B 20.69B 8.02B 100B 8.04B 7.87B | 325B 2.02B 1.76B 1.62B 1.51B 2.86B 192B 2.91B 19.5B 7.56B 94.25B 7.58B 7.41B |
| Net Debt | -76.78B -477M -417M -383M -357M -677M -45.43B -688M -4.61B -1.79B -22.28B -1.79B -1.75B | -391B -2.43B -2.12B -1.95B -1.82B -3.45B -231B -3.51B -23.49B -9.1B -114B -9.13B -8.93B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 03/07/26 | ¥2,162.00 | +1.05% | 3,045,900 |
| 02/07/26 | ¥2,139.50 | +0.94% | 6,188,700 |
| 01/07/26 | ¥2,119.50 | -2.55% | 5,055,800 |
| 30/06/26 | ¥2,175.00 | +0.18% | 9,968,900 |
| 29/06/26 | ¥2,171.00 | +1.21% | 10,716,900 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- 4503 Stock
Select your edition
All financial news and data tailored to specific country editions
